Literature DB >> 24989713

Prolonged Activated Partial Thromboplastin Time: Difficulties in Discriminating Coexistent Factor VIII Inhibitor and Lupus Anticoagulant.

Paul R J Ames1, Maria Graf2, Jeremy Archer3, Nicola Scarpato2, Luigi Iannaccone4.   

Abstract

To review the diagnostic difficulties of a prolonged activated partial thromboplastin time (aPTT) when 2 inhibitors with opposite clinical presentations coexist, we searched MEDLINE from January 1970 to November 2013 using acquired, factor VIII (FVIII), factor IX, hemophilia A and B, inhibitor, lupus anticoagulant (LA), antiphospholipid, anticardiolipin, anti-β2-glycoprotein I, antibodies, syndrome, bleeding, and thrombosis. We identified 13 articles for a total of 15 cases of possible coexistence of FVIII inhibitor and LA. The presenting clinical manifestation was thrombosis in 6 cases and bleeding in 9 cases. Activated partial thromboplastin time was the presenting laboratory abnormality in all cases, and first-line investigations suggested the coexistence of LA and acquired FVIII inhibitor. None of the articles addressed the diagnostic accuracy of the screening tests by performing "second line" assays. We reviewed the diagnostic pitfalls of the cases under study and provide some guidance for alternative tests when facing a prolonged aPTT that may have a double meaning.
© The Author(s) 2014.

Entities:  

Keywords:  acquired hemophilia; lupus anticoagulant

Mesh:

Substances:

Year:  2014        PMID: 24989713     DOI: 10.1177/1076029614541516

Source DB:  PubMed          Journal:  Clin Appl Thromb Hemost        ISSN: 1076-0296            Impact factor:   2.389


  4 in total

1.  A combined approach using global coagulation assays quickly differentiates coagulation disorders with prolonged aPTT and low levels of FVIII activity.

Authors:  Tomoko Matsumoto; Keiji Nogami; Midori Shima
Journal:  Int J Hematol       Date:  2016-10-11       Impact factor: 2.490

2.  Co-existent Acquired Haemophilia and Lupus Anticoagulant. A Thorny Issue.

Authors:  Paul R J Ames; Daniel Montero; Jeremy Archer
Journal:  Indian J Hematol Blood Transfus       Date:  2015-07-22       Impact factor: 0.900

3.  System performance evaluation of the cobas t 711 and cobas t 511 coagulation analyzers in routine laboratory settings.

Authors:  Steve Kitchen; Moniek de Maat; Michael Nagler; Robert Jones; Anna Lowe; John Burden; Kai Groneberg; Gergely Rozsnyai
Journal:  Blood Coagul Fibrinolysis       Date:  2020-10       Impact factor: 1.061

4.  Concomitant factor VIII inhibitor and lupus anticoagulant in an asymptomatic patient.

Authors:  Jeremy W Jacobs; Savanah D Gisriel; Krishna Iyer; Henry M Rinder
Journal:  J Thromb Thrombolysis       Date:  2021-10-25       Impact factor: 2.300

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.